Refine by
Biobanked Articles & Analysis: This-Year
4 articles found
Many oncology drugs have been abandoned by pharmaceutical companies due to poor performance in phase I, II, or III clinical trials. These drugs represent untapped potential treatments for indications outside of those initially investigated. With research and development costs for a single new drug estimated between $2–3 billion, abandoned drugs represent an opportunity to bring drugs to ...
The Predictive Oncology machine learning approach paired with our proprietary biobank of frozen dissociated tumor cells (DTCs) offers a screening opportunity for many repurposing candidates to be assessed, with outputs from this effort reflective of both confident predictions (Machine Learning) and wet lab ...
In this white paper, Predictive Oncology (POAI) highlights a recent successful project in partnership with the University of Michigan Natural Products Discovery Core (NPDC) through the ACE program. The ACE program supports academic researchers in their early drug discovery and development initiatives by providing access to the POAI proprietary active machine learning platform and ...
· Stable and Scalable Systems – The ability to cryopreserve organoids in biobanks and expand them indefinitely arises from their self-renewal capabilities, stem cell differentiation, and inherent self-organization, resulting in a reliable and consistent research model. ...